AEON Biopharma, Inc. (AEON)
(Delayed Data from AMEX)
$0.96 USD
-0.01 (-1.06%)
Updated Aug 23, 2024 03:59 PM ET
2-Buy of 5 2
F Value D Growth A Momentum F VGM
Balance Sheet
Fiscal Year End for AEON Biopharma, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 5 | 0 | 1 | 0 | -99,999 |
Receivables | 0 | 0 | 0 | 0 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 0 | 0 | 0 | 0 | NA |
Other Current Assets | 1 | 0 | 0 | 0 | NA |
Total Current Assets | 6 | 0 | 1 | 0 | NA |
Net Property & Equipment | 0 | 0 | 0 | 0 | NA |
Investments & Advances | 0 | 0 | 0 | 0 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 0 | 0 | 0 | 0 | NA |
Intangibles | 0 | 0 | 0 | 0 | NA |
Deposits & Other Assets | 0 | 279 | 276 | 0 | NA |
Total Assets | 7 | 279 | 277 | 0 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 3 | 3 | 1 | 0 | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 6 | 0 | 0 | 0 | NA |
Income Taxes Payable | 0 | 1 | 0 | 0 | NA |
Other Current Liabilities | 4 | 0 | 0 | 0 | NA |
Total Current Liabilities | 13 | 4 | 1 | 0 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 147 | 285 | 293 | 0 | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | NA |
Total Liabilities | 160 | 289 | 294 | 0 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | NA |
Common Stock (Par) | 0 | 0 | 0 | 0 | NA |
Capital Surplus | 381 | 0 | 0 | 0 | NA |
Retained Earnings | -474 | -9 | -17 | 0 | NA |
Other Equity | -61 | 0 | 0 | 0 | NA |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | -153 | -9 | -17 | 0 | NA |
Total Liabilities & Shareholder's Equity | 7 | 279 | 277 | 0 | NA |
Total Common Equity | -153 | -9 | -17 | 0 | 0 |
Shares Outstanding | 37.10 | 34.50 | 34.50 | 6.90 | NA |
Book Value Per Share | -4.13 | -0.27 | -0.49 | 0.00 | 0.00 |
Fiscal Year End for AEON Biopharma, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 3 | 2 | 5 | 16 | 0 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 1 | 1 | 0 |
Total Current Assets | 4 | 3 | 6 | 17 | 1 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 21 |
Total Assets | 6 | 3 | 7 | 18 | 22 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 1 |
Accounts Payable | 3 | 7 | 3 | 4 | 7 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 4 | 2 | 6 | 7 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 1 | 2 |
Other Current Liabilities | 4 | 7 | 4 | 3 | 0 |
Total Current Liabilities | 10 | 16 | 13 | 14 | 9 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 13 | 5 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 9 | 147 | 125 | 24 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 34 | 201 | 160 | 139 | 33 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 400 | 393 | 381 | 362 | 0 |
Retained Earnings | -428 | -592 | -474 | -423 | -11 |
Other Equity | 0 | 0 | -61 | -61 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -28 | -198 | -153 | -122 | -11 |
Total Liabilities & Shareholder's Equity | 6 | 3 | 7 | 18 | 22 |
Total Common Equity | -28 | -198 | -153 | -122 | -11 |
Shares Outstanding | 39.10 | 38.10 | 37.10 | 37.10 | 8.90 |
Book Value Per Share | -0.71 | -5.21 | -4.13 | -3.28 | -1.29 |